Chronic News and Research

RSS

Interim data from Cytheris CYT107 Phase I/IIa combination study on HCV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.

9 Nov 2011

Scripps scientist receives Novo Nordisk grant for research into diabetes

Andrew Butler, an associate professor in The Scripps Research Institute's Department of Metabolism and Aging, has been awarded one million dollars in funding over the next two years to further his research into a novel protein with the potential to improve the understanding and future treatment of diabetes.

9 Nov 2011

Inova Labs secures $17.5M in Series B round of equity financing

Inova Labs, a privately held medical device company focused on developing innovative products for the Chronic Obstructive Pulmonary Disease (COPD) market, announced today that it has secured a Series B round of equity financing for up to $17.5M from an investment syndicate led by Latterell Venture Partners, based in San Francisco, Calif.

9 Nov 2011

State roundup: Kansas Medicaid announcement; pilot projects for nursing homes, C-sections; Calif. marijuana clinics

Gov. Sam Brownback, Lt. Gov. Jeff Colyer and three Cabinet officials have scheduled a news conference for 10 a.m. Tuesday to describe details of their plan for making over the Kansas Medicaid program. ... The plan is expected to include a significant expansion of managed care.

9 Nov 2011

Laser therapy to turn brown eyes blue

A laser treatment developed by Stroma Medical's Dr. Gregg Homer takes only 20 seconds to perform but can turn brown eyes into blue ones permanently.

8 Nov 2011

New results from BioCryst's BCX4208 Phase 2b gout study

BioCryst Pharmaceuticals, Inc. presents new results from its Phase 2b randomized, double-blind, dose-response study of BCX4208 in patients with gout who have failed to reach the clinically important serum uric acid (sUA) goal of <6 mg/dL on allopurinol alone.

8 Nov 2011

Computer-tailored intervention may have positive effects on eating behaviors in adolescents

A web-based computer-tailored intervention aiming to increase physical activity, decrease sedentary behavior, and promote healthy eating among adolescents was not associated with positive long-term outcome measures, but may have positive short-term effects on eating behaviors, according to a report published Online First by Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

8 Nov 2011

UM launches campaign on medication adherence in Baltimore

Months before U.S. Surgeon General Regina Benjamin, MD, MBA, came to Baltimore on Nov. 2 to officially launch the city's leg of a three-year national campaign to raise awareness about medication adherence, pharmacy students had already taken up the challenge, said Cherokee Layson-Wolf, PharmD, CGP, associate professor of pharmacy practice and science at the University of Maryland School of Pharmacy.

8 Nov 2011

CWRU to establish umbrella program for integrative oncology

Case Western Reserve University School of Medicine is honored to announce gifts to establish the inaugural Parker Hannifin - Helen Moss Cancer Research Foundation Professorship in Integrative Oncology. This professorship will establish the School of Medicine and its affiliate hospitals as national leaders in teaching, research, and patient care in the field of integrative oncology.

8 Nov 2011

QRxPharma receives date for US pain drug launch, pending approval

Australian pain-relief drug developer QRxPharma (QRX) has announced today that they have received from the US Food & Drug Adminstration.

8 Nov 2011

High-field MRI can reveal tiny brain injuries in preterm infant

Pediatric neuroscientists at Oregon Health & Science University Doernbecher Children's Hospital are the first to use high magnetic field strength MRI to reveal tiny white matter injuries in the developing brain previously undetectable using standard MRI.

8 Nov 2011

MBL-HCV1 can reduce viral load in liver transplant patients

A human monoclonal antibody developed by MassBiologics of the University of Massachusetts Medical School (UMMS) given to patients with chronic hepatitis C virus (HCV) infection undergoing liver transplantation significantly suppressed the virus for at least a week after transplant and delayed the time to viral rebound.

8 Nov 2011

Economic burden of chronic hepatitis C-related liver disease

Health care costs for hepatitis C patients with end-stage liver disease are nearly 2.5 times higher than those in the early stages, according to a Henry Ford Hospital study.

8 Nov 2011

First large-scale study to address treatment of prescription opioid addiction

Individuals addicted to prescription painkillers are more likely to succeed in treatment with the aid of the medication buprenorphine-naloxone (Suboxone), report McLean Hospital and Harvard Medical School researchers in today's online edition of the Archives of General Psychiatry.

8 Nov 2011

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

Pfizer Oncology will present data on a number of investigational compounds from its hematology portfolio, including new data from bosutinib in chronic myeloid leukemia (CML), inotuzumab in non-Hodgkin lymphoma (NHL), as well as the first presentation of clinical data for PF-04449913, which inhibits Smoothened (SMO), a key component of the Hedgehog pathway.

7 Nov 2011

Gilead, CRF commence ranolazine Phase 3 clinical trial for chronic stable angina in post-PCI setting

Gilead Sciences, Inc. and the Cardiovascular Research Foundation (CRF) today announced the initiation of RIVER-PCI (Ranolazine for Incomplete VEssel Revascularization post-PCI), a Phase 3 clinical trial evaluating the utility of ranolazine to prevent major adverse cardiovascular events (MACE) in patients with a history of chronic angina who have incomplete revascularization following percutaneous coronary intervention (PCI).

7 Nov 2011

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Pharmacyclics, Inc. today reported financial results and recent developments for its fiscal first quarter ended September 30, 2011.

7 Nov 2011

Gifts established at Case Western Reserve to educate physicians in integrative oncology

7 Nov 2011

MILV subsidiary acquires formula to restore proper kidney function

Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. announced that it has executed the formal closing documents and acquired the chronic kidney disease formula. This formula was developed to restore proper kidney function.

7 Nov 2011

ISET 2012 to discuss latest advances in chronic cerebrospinal venous insufficiency

Innovators in the field of endovascular therapy will explore the often-contentious topic of chronic cerebrospinal venous insufficiency (CCSVI), which is theorized to be a contributing factor in the development of multiple sclerosis (MS), at the 24th annual International Symposium on Endovascular Therapy.

7 Nov 2011